Biopharmaceutical royalties buyer Royalty Pharma plc (Nasdaq:RPRX) said on Wednesday that it has entered into an agreement with biotechnology company Biogen Inc (Nasdaq:BIIB) to provide up to USD250m in research and development funding for litifilimab, a first-in-class biologic in Phase 3 trials for systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE).
Litifilimab has demonstrated proof-of-concept and a well-tolerated safety profile in both conditions, with results published in the New England Journal of Medicine. It has the potential to be the first targeted biologic approved for CLE, a disease with no currently available treatments.
Biogen expects Phase 3 trial results between 2026 and 2027.
Under the deal, Royalty Pharma will provide funding over six quarters in exchange for regulatory milestones and mid-single-digit royalties on global sales.
Viatris receives Japanese approval for WAKIX in narcolepsy and sleep apnoea
WHO identifies SynAct Pharma's resomelagon among six dengue drug candidates
Japan approves subcutaneous Leqembi formulation for early Alzheimer's disease
Japan approves Lundbeck's eptinezumab for preventive migraine treatment
Skyhawk Therapeutics reports final results from Phase 1/2 trial in Huntington's disease
GSK to acquire trispecific T cell-engager from Chimagen for multiple myeloma
Kelun-Biotech publishes phase III data for trastuzumab botidotin in HER2-positive breast cancer
FDA grants priority review to Takeda's zasocitinib application for plaque psoriasis
Armata Pharmaceuticals announces receipt of FDA Breakthrough Therapy Designation for AP-SA02
AstraZeneca's Etcamah misses primary endpoint in Phase III breast cancer trial
GSK reports positive Jideytro data supporting potential first-line lung cancer use
Eloxx Pharmaceuticals commences Phase 2b study of exaluren
Akeso presents positive results from registrational Phase III study of ivonescimab
FDA grants Priority Review to Genentech's Enspryng for MOGAD